PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy is a research paper published in The Journal of Experimental Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 28 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
U.S. Department of Defense
Grant: BC200100
National Institutes of Health
Grant: CA269662
National Institutes of Health
Grant: CA260239
National Institutes of Health
Grant: CA290792
NCI NIH HHS
Grant: R01 CA290792
NCI NIH HHS
Grant: R01 CA260239
NCI NIH HHS
Grant: R01 CA203834
NCI NIH HHS
Grant: R01 CA269661
NCI NIH HHS
Grant: T32 CA257923
National Institutes of Health
Grant: 1R01CA290792-01
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy
National Institutes of Health
Grant: 5R01CA260239-05
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis
Dr. and Mrs. James Robert Spenser Family
Sanofi
Congressionally Directed Medical Research Programs
FWCI
4.63
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals